Onward is moving its ARC-EX system towards commercial launch, having submitted a De Novo application to the US Food and Drug Administration in April 2024. The analysis of stimulation parameters ...

Onward’s ARC-EX delivers targeted, programmed spinal cord stimulation non-invasively, rather than via implanted electrodes. The therapy is being used to help restore limb function in patients ...